# Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19

> **NCT04567173** · PHASE2,PHASE3 · TERMINATED · sponsor: **University of the Philippines** · enrollment: 44 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Anti-SARS-CoV-2 convalescent plasma

## Key facts

- **NCT ID:** NCT04567173
- **Lead sponsor:** University of the Philippines
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-21
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Limited enrolment (unable to achieve target sample size)
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04567173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04567173, "Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04567173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*